First Ascent Biomedical is a pioneering biotech company dedicated to transforming oncology through its innovative Drug Prediction Platform (DxPP). This first-of-its-kind system integrates functional drug testing, DNA/RNA sequencing, and AI-driven tumor analysis to develop personalized treatment plans for cancer patients. By rapidly growing therapy-resistant cells from patient samples and testing them against hundreds of FDA-approved drugs, DxPP identifies the most effective therapies tailored to each individual's tumor vulnerabilities. This approach delivers actionable treatment recommendations to physicians within an average of 10 days, offering new hope to patients who have exhausted standard therapies.